Nachrichten zur Travere Therapeutics Inc. Aktie

Travere Therapeutics sichert beim Hauptprodukt FILSPARI im April eine wichtige FDA-Zulassungserweiterung zur Behandlung von FSGS. FILSPARI könnte langfristig Spitzenumsätze…

…

…

By John Vandermosten, CFANASDAQ:LGNDREAD THE FULL LGND RESEARCH REPORTLigand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2025 results with revenues of $268 million…

…

Travere Therapeutics shares fall after the FDA extends its review timeline for Filsparis sNDA in FSGS, pushing the decision date…

Travere Therapeutics stock hits 52-week high at 37.12 USD…

…

Travere Therapeutics soars as FILSPARI sales surge in third quarter…

Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth…

Travere Therapeutics stock falls on FDA review setback…

…

…

…

Travere Therapeutics stock rises on sNDA submission plans for FILSPARI…

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management…

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of…

Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.…

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating…

After-hours movers: Costco, Scholastic Corp, Travere Therapeutics…

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September…

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management…

…

…

SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will…

SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March…